Featured Innovator

Houston entrepreneur is using his analytics company to change the oil and gas industry

Luther Birdzell, founder and CEO of Houston-based OAG Analytics is on a mission to democratize data for his upstream oil and gas clients. Courtesy of OAG Analytics

Luther Birdzell has been on a mission to democratize data for the upstream oil and gas industry since he started his company, OAG Analytics, in 2013.

For him, there's just not enough data scientists for hire to do the same thing internally for different companies. He thought of a way where he can give clients an easy-to-use platform to have access to data that could save oil and gas companies millions of dollars. So, that's exactly what he did.

"Over the past five and a half years, we've built that platform," Birdzell says. "We are currently helping to optimize over $1 billion in capital deployment around drilling and completions."

The company has grown to 25 employees and tripled its revenue last year. The team is forecasting another year of high grow for 2019.

Birdzell spoke with InnovationMap to talk about his start in software, the company's growth, and why nonprofit work has been important to him as a business leader.

InnovationMap: Did you always know you wanted to be an entrepreneur?

Luther Birdzell: When I was about two years old, my grandfather ran a meat business in New York City — in the meatpacking district, back when that area actually had meat packers. It just was in my bones from a really young age that I wanted to start a business.

IM: How did you get into software development?

LB: I studied electrical engineering in college. For my first seven years, I worked within consulting, implementing systems that made data more valuable to subject matter experts. I was primarily supporting management teams and mostly tech teams.

Then, I met the founders of iTKO, who were doing software testing for clients, and I helped them figure out a way that was complementary to what they were doing. We took a capability that can enable software developers that can help companies reduce their data center costs by a lot. It was a capability that was really restricted to specialized programing. Together we figured out how to make that a capability that anyone in an IT company used. That resulted in companies being able to higher fewer people to maintain servers, as well as reduce other costs. Companies were saving of millions of dollars per year per project.

IM: When did the idea for OAG come to you?

LB: Computer Associates bought iTKO from us in 2011. When I resigned from CA in 2013, it was very clear to me that artificial intelligence, big data, machine learning, and the cloud, were all tech ingredients for adding more value to data. Then the oil and gas business came into focus.

When I founded OAG Analytics, our mission then — and still is today — was to build a platform for the upstream oil and gas industry that enables them to manage their data, introduces world-class machine learning in minutes without having to write a single line of code, and allow them to run simulations on the resulting analysis.

IM: What makes OAG successful?

LB: My vision was to create a platform that could be trusted to support billions of dollars of capital optimization through transparency and control. A black box doesn't work for the kind of problems we're helping our customers optimize. They need something that's easy to use, simple, powerful, and also gives them complete control.

IM: What's the barrier of success for your clients?

LB: We have customers who have increased their capital efficiency on drilling programs that are about $500 million by over 25 percent, while still getting the same amount of oil out of the ground.

IM: What was the early reception like?

LB: We found a lot of interest in talking about how it works. In 2013, 2014, 2015, well over half the industry knew enough about this technology from other industries to have high confidence that it would affect the oil and gas industry one day. They were willing to spend an hour or two on what it is and how it works. But the number of companies who were really willing to invest in a meaningful way was really small.

There were companies, like EOG Resources, for example started spending millions of dollars developing this technology in house. Other companies seeing EOG and Anadarko success, raised the bar on the level of proof.

There's an increasing number of companies in the industry who realize that AI isn't a futuristic thing anymore. There are companies using it today, and the companies using it right are making more money. But, they're learning it's hard to do right. It could take years and millions of dollars to develop this yourself, but we're helping companies get up to speed in a matter of months, and our total cost for the first year is well under a million bucks to do this. They want us to train them how to use it, then act as support, rather than run it all for them.

IM: Do you plan to stay in just upstream oil and gas?

LB: We're 100 percent focused on upstream oil and gas, and always have been, but as we continue to grow, we're going to follow the market and what customers want. Repurposing our platform for other applications in oil and gas, energy, and even beyond that. We're evaluating. The vision has always been to democratize AI, and oil and gas is where we started.

IM: Do you have an exit strategy?

LB: As far as exits, I get asked this a lot. I don't believe in exit strategies. I believe in building a great company. I've seen a lot of founders make a lot of mistakes trying to cut corners to get to early exits. Our goal is to be a great company, and that starts with the right vision and then getting the right people and hires.

IM: How has Houston been as a place to have a startup in energy?

LB: Houston is unparalleled in the oil patch or the ability to support day trips. There's two airports and tons of direct flights to other cities in the oil patch. It's the only city you can cover all the other cities from with day trips. The efficiency of being able to be on site with customers is such an advantage.

There are a lot of industry experts in and around Houston, but a startup software company works very differently from an oil company. I think we have a long road ahead of us before we have an ecosystem in place to support startups and give them the best chance of success. Some of that comes from advisers, some from the ecosystem, and some part of it just takes time. But once those pieces come into play, talent follows. I think Houston is a very natural hub for energy tech.

IM: Volunteering is an important part of your business. Why is that something you've focused on?

LB: Something in the DNA of our business is giving back. We do that through direct community action. We've volunteered as a company, and we're always on the lookout for ways we can engage with and make the most contribution to the community. We do this primarily for personal reasons, but the universe has been very generous over my career with reciprocating a professional upside.

You volunteer in high school to get into college, then maybe some in college. And you might think, "oh that's for philanthropists or retired people and I'll get back to that later." But the reality of that is it feels better doing some of that now, so we do.

------

Portions of this interview have been edited.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted